Press Releases

Date Title and Summary Additional Formats
Toggle Summary FDA Grants Exemption to Import Alert for Cellectar’s CLR 131 in Pediatric and Adolescent Patients
Company to initiate Phase 1 study in pediatric and adolescent patients with select relapsed or refractory solid tumors, lymphomas and malignant brain tumors FLORHAM PARK, N.J. , March 19, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences , Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical
View HTML
Toggle Summary Cellectar Reports Financial Results for Year Ended December 31, 2018 and Provides a Corporate Update
FLORHAM PARK, N.J. , Feb. 26, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences , Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced financial results for the year ended
View HTML
Toggle Summary Cellectar Reports Positive Top-line Response Rate of 30% from R/R Multiple Myeloma Cohort in Ongoing Phase 2 Study of CLR 131
Company’s lead product candidate previously demonstrated positive top-line results from the diffuse large B-cell lymphoma cohort of this study Dosing in multiple tumor types is ongoing; Cellectar intends to report additional data this year FLORHAM PARK, N.J. , Feb.
View HTML
Toggle Summary Cellectar Biosciences to Present at the Annual BIO CEO & Investor Conference
FLORHAM PARK, N.J. , Feb. 05, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences , Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that James Caruso, president and chief
View HTML
Toggle Summary Cellectar Biosciences to Present at NobleConXV, Noble Capital Markets’ Fifteenth Annual Investor Conference
FLORHAM PARK, N.J. , Jan. 23, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences , Inc. (NASDAQ:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that James Caruso, president and chief
View HTML
Toggle Summary Cellectar Provides Update on Phase 1 Trial of CLR 131 in Relapsed/Refractory Multiple Myeloma
Median overall survival of 22.0 months observed in Cohorts 1-4 FLORHAM PARK, N.J. , Jan. 07, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer,
View HTML
Toggle Summary Cellectar Biosciences to Present at the Biotech Showcase
FLORHAM PARK, N.J. , Jan. 03, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, announces that James Caruso , president and chief executive
View HTML
Toggle Summary Cellectar Granted Japanese Patent for CLR 131
Patent covers composition of matter and use in solid and liquid tumor cancer indications FLORHAM PARK, N.J. , Dec. 11, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of
View HTML
Toggle Summary Cellectar Initiates Cohort 6 of Phase 1b Trial Evaluating CLR 131 in Relapsed/Refractory Multiple Myeloma
Patient enrolled at highest fractionated two-dose regimen to date FLORHAM PARK, N.J. , Dec. 04, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer,
View HTML
Toggle Summary Cellectar Reports Third Quarter 2018 Financial Results and Provides Business Update
FLORHAM PARK, N.J. , Nov. 13, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (“Cellectar” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today reported financial
View HTML